Should You Buy This Biotech Stock Before It Starts Soaring?
Milestone Pharmaceuticals (NASDAQ: MIST) expects to report top-line data from its phase 3 Node-301 clinical trial before the end of the month. If positive, the company expects to use the trial results to file for approval with the U.S. Food and Drug Administration (FDA). The company believes its drug etripamil marks the first self-administered drug to rapidly stop episodes of exceedingly rapid heart rate known as paroxysmal supraventricular tachycardia (PSVT).
Image source: Getty Images.
Patients with PSVT experience episodes of rapid heart rate, sometimes over 200 beats per minute, that start and stop without warning. The unknown timing of these attacks can seriously impair the quality of life for patients. PSVT can only be diagnosed during an on-going episode, making accurate diagnosis challenging.
Source Fool.com
